We applaud the efforts of Lakatos et al. 1 in their attempt to achieve a "bloodless" solution to the treatment of ABO hemolytic disease in a newborn of Jehovah's Witness parents. However, we were somewhat surprised that they did not even mention the use of intravenous immune globulin, an alternative therapeutic regimen that has been well tested and has proven to be effective in the treatment of isoimmune hemolytic jaundice in the neonate. [2] [3] [4] [5] Although the efficacy of D-penicillamine in reducing jaundice was first demonstrated in the 1970's, this drug does not seem to have gained acceptance in the international neonatal community. In fact, according to the literature, it still appears to be used only by the Lakatos group in Hungary. We surmise that this lack of acceptance is related to the multiple potential toxic effects reported with the use of D-penicillamine, toxicities which, in the extreme, can lead to fatalities. 6 In contrast, intravenous immune globulin has minimal toxicity, 7 proven efficacy, and offers an alternative "bloodless" solution to the Coombs' positive ABO problem in affected neonates. A bloodless approach to the treatment of neonatal hemolytic jaundice has implications not just for infants of Jehovah's Witnesses, but for all newborns in the current era of potentially infected blood supplies. We caution readers to consider all available treatment options before embarking on a therapeutic course in any specific infant.
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Surely your readers will recognize that intravenous immune globulin is a blood product, and, as a result, is unacceptable to Jehovah's Witness families. Note also that the cost of D-penicillamine treatment (approximately $2 (U.S.) per patient) is considerably less than intravenous immune globulin. The comments about lack of "acceptance" of D-penicillamine treatment seem sadly parochial to us, because this therapy has been used extensively in Hungary for Ͼ26 years. In our own experience, Ͼ20,000 neonates have been treated without side effects. In addition, six other favorable reports have been published in Hungarian periodicals; 1-6 the last report, 6 published in the year 2000, notes the use of D-penicillamine therapy in Rh-hemolytic disease. [1] [2] [3] [4] [5] [6] The successful use of erythropoietin in the treatment of severe anemia in a neonate, reported in our paper, should also be of considerable practical interest to your readers.
